Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype

Introduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC...

Full description

Bibliographic Details
Main Authors: B C M Hermans, J L Derks, H J M Groen, J A Stigt, R J van Suylen, L M Hillen, E C van den Broek, E J M Speel, A-M C Dingemans
Format: Article
Language:English
Published: Bioscientifica 2019-12-01
Series:Endocrine Connections
Subjects:
Online Access:https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xml
id doaj-72a03e609bec496c9e62c8012b2c040a
record_format Article
spelling doaj-72a03e609bec496c9e62c8012b2c040a2020-11-25T02:07:51ZengBioscientificaEndocrine Connections2049-36142049-36142019-12-0181216001606https://doi.org/10.1530/EC-19-0372Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtypeB C M Hermans0J L Derks1H J M Groen2J A Stigt3R J van Suylen4L M Hillen5E C van den Broek6E J M Speel7A-M C Dingemans8Department of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, University of Groningen and University Medical Centre, Groningen, The NetherlandsDepartment of Pulmonary Diseases, Isala Hospital, Zwolle, The NetherlandsPathology-DNA, Jeroen Bosch Hospital, ‘s Hertogenbosch, The NetherlandsDepartment of Pathology, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsPALGA Foundation, Utrecht, The NetherlandsDepartment of Pathology, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsIntroduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up. Methods: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1). Results: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI wa s 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found. Conclusion: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype. https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xmllarge cell neuroendocrine carcinomalcnecsolitary brain metastasisprognosiski-67
collection DOAJ
language English
format Article
sources DOAJ
author B C M Hermans
J L Derks
H J M Groen
J A Stigt
R J van Suylen
L M Hillen
E C van den Broek
E J M Speel
A-M C Dingemans
spellingShingle B C M Hermans
J L Derks
H J M Groen
J A Stigt
R J van Suylen
L M Hillen
E C van den Broek
E J M Speel
A-M C Dingemans
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
Endocrine Connections
large cell neuroendocrine carcinoma
lcnec
solitary brain metastasis
prognosis
ki-67
author_facet B C M Hermans
J L Derks
H J M Groen
J A Stigt
R J van Suylen
L M Hillen
E C van den Broek
E J M Speel
A-M C Dingemans
author_sort B C M Hermans
title Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
title_short Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
title_full Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
title_fullStr Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
title_full_unstemmed Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
title_sort large cell neuroendocrine carcinoma with a solitary brain metastasis and low ki-67: a unique subtype
publisher Bioscientifica
series Endocrine Connections
issn 2049-3614
2049-3614
publishDate 2019-12-01
description Introduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up. Methods: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1). Results: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI wa s 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found. Conclusion: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.
topic large cell neuroendocrine carcinoma
lcnec
solitary brain metastasis
prognosis
ki-67
url https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xml
work_keys_str_mv AT bcmhermans largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT jlderks largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT hjmgroen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT jastigt largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT rjvansuylen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT lmhillen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT ecvandenbroek largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT ejmspeel largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
AT amcdingemans largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype
_version_ 1724929199548923904